Last Updated: September 24, 2026

Details for New Drug Application (NDA): 211155


✉ Email this page to a colleague

« Back to Dashboard


NDA 211155 describes COPIKTRA, which is a drug marketed by Secura and is included in one NDA. It is available from one supplier. There are six patents protecting this drug. Additional details are available on the COPIKTRA profile page.

The generic ingredient in COPIKTRA is duvelisib. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the duvelisib profile page.
Summary for 211155
Tradename:COPIKTRA
Applicant:Secura
Ingredient:duvelisib
Patents:6
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 211155
Generic Entry Date for 211155*:

⤷  Start Trial

Constraining patent/regulatory exclusivity:

8,193,182

Dosage:

CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Suppliers and Packaging for NDA: 211155
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
COPIKTRA duvelisib CAPSULE;ORAL 211155 NDA Secura Bio, Inc 73116-215 73116-215-28 28 CAPSULE in 1 PACKAGE (73116-215-28)
COPIKTRA duvelisib CAPSULE;ORAL 211155 NDA Secura Bio, Inc 73116-215 73116-215-56 56 CAPSULE in 1 PACKAGE (73116-215-56)

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrength15MG
Approval Date:Sep 24, 2018TE:RLD:Yes
Patent:11,312,718Patent Expiration:Jan 10, 2032Product Flag?YSubstance Flag?Delist Request?
Patent:12,213,983Patent Expiration:Apr 26, 2035Product Flag?Substance Flag?Delist Request?
Patented Use:FOR THE TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND/OR SMALL LYMPHOCYTIC LEUKEMIA (SLL)
Patent:8,193,182Patent Expiration:Sep 24, 2032Product Flag?Substance Flag?YDelist Request?

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

 
© Copyright 2002-2026 thinkBiotech LLC
ISSN: 2162-2639
Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
 NCE-1 Patent Challenge Dates 2026 - 2027
Preferred Citation:

Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
   See Primary Research Papers Citing DrugPatentWatch

Links